Decoy Therapeutics Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
DCOY$1.11+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months EndedMarch 31 | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net loss | $(1,709,533) | $(1,715,290) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 1,106 | 1,107 |
| Equity-based compensation expense | 33,534 | 77,508 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 46,328 | 175,052 |
| Accounts payable | 254,645 | 111,104 |
| Accrued expenses and other current liabilities | 192,206 | (3,436) |
| Net cash used in operating activities | (1,181,714) | (1,353,955) |
| Financing activities | ||
| Proceeds from issuance of equity securities, net | 655,202 | 38 |
| Payments on note payable | (109,636) | (172,788) |
| Net cash (used in) provided by financing activities | 545,566 | (172,750) |
| Net decrease in cash and cash equivalents | (636,148) | (1,526,705) |
| Cash, cash equivalents and restricted cash at beginning of period | 2,434,528 | 5,899,910 |
| Cash, cash equivalents and restricted cash at end of period | $1,798,380 | $4,373,205 |
| Supplemental disclosure of cash flow information: | ||
| Non-cash investing and financing activities: | ||
| Cash paid for interest | $4,094 | $4,019 |
| Accrued issuance costs for issuance of equity securities | $429,032 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.